Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Administrative Information / Freedom of Information Act

Freedom of Information Act

Information about the Freedom of Information Act and how it pertains to the Early Detection Research Network.

The Freedom of Information Act (FOIA), 5 U.S.C. 552 provides individuals with a right to access information in the possession of the U.S. federal government. The government, however, may withhold information covered by 9 exemptions and 3 exclusions contained in the Act.

Before submitting a request under FOIA, individuals should try to determine whether the information sought is already in the public domain and whether it is or may be held by the National Cancer Institute (NCI). NCI has a wealth of information available in both published and electronic formats. A search of the EDRN web Site,, can be helpful in locating information and lists of available publications.

If data produced under an NCI grant are sought, the data will be released under FOIA only if specific requirements are met.

It is important to note that FOIA allows agencies to recover part of the costs associated with responding to requests. Department of Health and Human Services regulations describe specific rules for fees, requesting a fee waiver, and reducing fees.

Questions about FOIA and requests for information held by NCI can be directed either to the NCI FOIA Office or to the National Institutes of Health (NIH) FOIA Office.

The NCI FOIA Office is located at:

Building 31, Room 10A48
31 Center Drive
Bethesda, MD 20892
Telephone: 301-496-2999
Fax number: 301-435-2931

 The NIH FOIA Office is located at:

Building 31, Room 5B35
31 Center Drive
Bethesda, MD 20892
Telephone: 301-496-5633
Fax number: 301-402-4541
New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.